批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/07/30 |
SUPPL-33(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/10/24 |
SUPPL-32(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/11/16 |
SUPPL-30(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/11/01 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/06/25 |
SUPPL-27(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/10/01 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/07/27 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/03/24 |
SUPPL-22(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2008/06/20 |
SUPPL-18(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2005/12/29 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/07/26 |
SUPPL-15(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2001/10/01 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1996/07/22 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1993/11/22 |
SUPPL-8(补充) |
Approval |
Labeling |
|
|
|
1992/03/31 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1992/02/19 |
SUPPL-7(补充) |
Approval |
Labeling |
|
|
|
1991/08/20 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1989/05/24 |
SUPPL-2(补充) |
Approval |
Labeling |
|
|
|
1988/11/07 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1987/12/24 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
002 |
7645801 |
2027/07/24 |
Y |
Y |
|
|
|
PDF格式 | |
与本品治疗等效的药品
活性成分:MESALAMINE 剂型/给药途径:ENEMA;RECTAL 规格:4GM/60ML 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
019618 |
001 |
NDA |
ROWASA |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
Yes |
Yes |
AB |
1987/12/24
|
MYLAN SPECIALITY LP |
076751 |
001 |
ANDA |
MESALAMINE |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
No |
No |
AB |
2004/09/17
|
PADAGIS ISRAEL |
019618 |
002 |
NDA |
SFROWASA |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
Yes |
No |
AB |
2008/06/20
|
MYLAN SPECIALITY LP |
216941 |
001 |
ANDA |
MESALAMINE |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
No |
No |
AB |
2023/05/30
|
ENCUBE |
活性成分:MESALAMINE 剂型/给药途径:ENEMA;RECTAL 规格:4GM/60ML 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
019618 |
001 |
NDA |
ROWASA |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
Yes |
Yes |
AB |
1987/12/24
|
MYLAN SPECIALITY LP |
076751 |
001 |
ANDA |
MESALAMINE |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
No |
No |
AB |
2004/09/17
|
PADAGIS ISRAEL |
019618 |
002 |
NDA |
SFROWASA |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
Yes |
No |
AB |
2008/06/20
|
MYLAN SPECIALITY LP |
216941 |
001 |
ANDA |
MESALAMINE |
MESALAMINE |
ENEMA;RECTAL |
4GM/60ML |
Prescription |
No |
No |
AB |
2023/05/30
|
ENCUBE |